Canadian HIV Technology Development Program funding
Funding under the CHVI is administered by the Canadian International Development Agency, Industry Canada, the Public Health Agency of Canada, the Canadian Institutes of Health Research, Health Canada and the Bill & Melinda Gates Foundation.
On March 3, 2011, small and medium enterprises (SMEs) in Canada were invited to submit project proposals for the new Canadian HIV Technology Development (CHTD) program. The CHTD falls under the Translating Basic Science into Clinical Trials program area of the Canadian HIV Vaccine Initiative (CHVI), a collaboration between the Government of Canada and the Bill & Melinda Gates Foundation.
The new CHTD, a component of the National Research Council's Industrial Research Assistance Program (NRC-IRAP), aims at advancing the development of a human immunodeficiency virus (HIV) vaccine and related technologies to prevent, diagnose, and treat HIV.
To be eligible for financial assistance under the CHTD, your business must:
- Be a small and medium-sized enterprise in Canada, incorporated and profit-oriented
- Have 500 or less full-time equivalent employees; and
- Have the objective to grow and generate profits through development and commercialization of innovative, technology-driven new or improved products, services, or processes in Canada.
For more information on the CHTD interested SMEs in Canada can call NRC-IRAP at 1-877-994-4727, or visit their website at: Industrial Research Assistance Program (IRAP)
For more information on this funding opportunity, please visit: Industrial Research Assistance Program Services
Report a problem or mistake on this page
- Date modified: